儿童噬血细胞综合征38例临床分析

摘要目的：探讨噬血细胞综合征患儿的临床特征、治疗及预后。方法：对38例噬血细胞综合征患儿的Il盏床症状、体征、试验检查结果、治疗及预后,进行回顾性总结与分析。结果：38例患儿主要表现为发热、肝脾淋巴结肿大、外周血细胞减少、铁蛋白升高、凝血功能异常;经针对性治疗后,治愈3例,好转20例,疗效不佳自动出院9例,死亡6例。结论：噬血细胞综合征病因复杂,临床表现多种多样,病情凶险,预后较差,旱期诊断及治疗对预后十分关键。     

胆管结石合并胆管癌的临床特征与诊治分析

目的：探讨胆管结石合并胆管癌的临床特征及诊治方法。方法：回顾性分析2000年1月-2009年12月我院收治的胆管结石合并胆管癌16例患者的临床病理资料。结果：胆管癌的发生率占同期胆管结石患者的3.1%,其临床表现以右上腹疼痛及反复的胆管炎发作为主,但缺乏特异性。术前胆管癌组患者AKP、γ-GT均有不同程度升高,ALT升高12例,总胆红素升高9例,与非胆管癌组相比,AKP、γ-GT、ALT、TBIL均显著升高（P〈0.01）,且胆管癌组术前血清CA19-9及CEA显著高于非胆管癌组（P〈0.01）,而两组间CA125及AFP水平比较无显著差异（P〉0.05）。16例患者中可进行手术治疗10例;其中根治性手术8例,姑息性手术2例。8例根治性手术患者的1、3年生存率分别为78.6%和36.4%;2例姑息性手术患者1、3年生存率分别为50.0%和0%,两组比较具有显著性差异（P〈0.05）。结论：胆管结石合并胆管癌的临床表现缺乏特异性,患者的疗效较差,对血清CA19-9和CEA显著升高者应行病理活检确诊,治疗手段应该力争实行根治性切除,有助于提高患者的生存期。     

miR396基因家族的进化及功能分析

MicroRNA(miRNA)是由约22个核苷酸组成的内源性非编码小分子RNA,广泛存在于真核细胞中,通过与靶基因的互补配对在转录后水平对基因表达进行调控,导致mRNA的降解或翻译抑制。本文通过对目前miRBase中收录的miR396家族进行生物信息学分析发现,该家族在植物界中高度保守,它们可能起源于较为古老的物种,经历长期复杂的进化过程而保留了下来;靶基因预测结果显示生长调控因子GRF为其主要靶标;启动子分析表明, miR396编码基因的上游存在光、温度、激素、厌氧、干旱及病害等胁迫响应相关的顺式作用元件,它们可与转录因子结合,参与多种胁迫应答反应。本文可为全面深入研究miRNA的作用机制奠定基础。     

对肝炎患者进行胆碱酯酶活性监测的临床意义分析

目的:血清胆碱酯酶活性(CHE)是反应肝细胞损害的灵敏指标,对于肝炎疾病的临床应用具有重大的价值,评估血清胆碱酯酶的活性变化是本文的主要目的.方法:对各种类型肝炎患者的CHE活性采用医院引进的国外先进的全自动生化分析仪进行检测,并对患病肝炎组与正常组进行胆碱酯酶活性的对照(P＜0.01).结果:三组肝炎患者在接触时间、基础疾病、血清肌酸激酶(CK)、昏迷时间等有差异有显著性(P＜0.01),在年龄、性别、中毒原因方面没有显著性差异(P＞0.05).迟发性脑病组和无迟发性脑病组在年龄、基础疾病、并发症、接触时间、昏迷时间、CK方面差异有显著性(P＜0.01);而在性别、中毒原因方面差异无显著性(P＞0.05).结论:最终结果表明,CHE活性检测对于判定肝炎患者的预后具有重大的价值和作用,应得到充分的重视,而广泛、有效的应用于临床.     

重复经颅磁刺激对脑卒中后患者神经功能缺损的改善

目的:探讨重复经颅磁刺激在脑卒中康复的应用及效果.方法:选择2010年9月至2012年9月在我院神经内科收治的58例脑卒中患者分为两组,即A组和B组,A组患者给予常规药物治疗和康复训练,B组患者在上述治疗的基础上加用低频重复经颅磁刺激治疗,比较两组患者美国国立卫生院神经功能缺损评分情况、日常生活活动(ADL)评分和不良反应发生情况.结果:治疗后,随着时间的推移,两组患者美国国立卫生院神经功能缺损评分得分逐渐下降(P＜0.05).B组患者2周后和6周后两个时点美国国立卫生院神经功能缺损评分得分明显低于A组患者的,差异有显著性(P＜0.05),而随着时间的推移,两组患者日常生活活动(ADL)评分得分逐渐上升(P＜0.05).B组患者2周后和6周后两个时点日常生活活动(ADL)评分得分明显高于A组患者的,差异有显著性(P＜0.05).两组患者在不良反应发生方面差异无显著性(P＞0.05).结论:低频重复经颅磁刺激治疗脑卒中单侧肢体功能障碍患者临床疗效确切,安全可靠,不良反应少.     

丁苯酞软胶囊联合奥扎格雷钠治疗短暂性脑缺血发作的临床观察

目的:探讨丁苯酞软胶囊联合奥扎格雷钠在短暂性脑缺血发作(TIA)病情治疗中的临床效果.方法:选取住院确诊为TIA患者60例,随机分为用药组和对照组,每组30例,对照组使用奥扎格雷钠治疗,用药组使用丁苯酞软胶囊和奥扎格雷钠联合治疗.观察两组的临床疗效.结果:用药组的终止发作时间短于对照组(P＜0.05).治疗后纤维蛋白原含量和甘油三酯含量与治疗前相比较,两种的变化差异均有统计学意义(P＜0.05),但两组治疗后纤维蛋白原含量和甘油三酯含量的分布上差异均有统计学意义(P＜0.05),用药组的治疗效果要明显优于对照组.两组3个月、6个月及9个月TIA复发率及卒中发生率差异有统计学意义(P＜0.05).结论:丁苯酞软胶囊与奥扎格雷钠联用治疗TIA安全有效,复发率及脑卒中的发生率低,值得临床广泛应用.     

脱发相关差异表达基因的生物信息学分析

利用生物信息学方法分析脱发相关差异表达基因,有望帮助了解脱发发生发展的分子机制。本研究从NCBI的子数据库GEO中选择基因表达谱GSE45512和GSE45513数据集,利用R语言limma工具包,筛选出两个物种斑秃样本与正常样本的共同显著差异表达基因。对这部分基因进行功能注释和蛋白互作网络分析,同时对全部差异表达基因进行基因集富集分析。结果发现,人头皮斑秃样本共筛选出225个差异表达基因;C3H/HeJ小鼠自发斑秃皮肤样本共筛选出337个差异表达基因;两个物种的共同显著差异表达基因有23个。GO功能富集分析和蛋白互作网络分析显示,这部分差异基因显著富集于免疫相关功能,并且彼此间存在蛋白互作关系。基因集富集分析显示两个物种的差异基因都能显著富集到趋化因子信号通路、细胞因子受体相互作用、金葡菌感染及抗原加工与呈递通路;而且人的下调差异基因不仅映射到了人类表型数据库的脱发表型,也映射到皮肤附属物病理相关表型。综上所述,本研究通过生物信息方法分析脱发皮肤组织与正常皮肤组织的差异表达基因,最终筛选出23个在人和小鼠中共同存在的显著差异表达基因;此外,分析发现脱发与免疫过程及皮肤附属物病变密切相关,这些结果为脱发的诊断和治疗提供了新思路。     

In silico identification of novel lncRNAs with a potential role in diagnosis of gastric cancer

Abstract

Gastric cancer (GC) is the second leading cause of cancer-related deaths in the world. Due to the shortage of adequate symptoms in the early stages, it is diagnosed when the tumor has spread to distant organs. Early recognition of GC enhances the chance of successful treatment. Molecular mechanisms of GC are still poorly understood. LncRNAs are emerging as new players in cancer in both oncogene and tumor suppressor roles. High-throughput technologies such as RNA-Seq, have revealed thousands of lncRNAs which are dysregulated in GC. In this study, we retrieved lncRNAs obtained by High-throughput technologies from OncoLnc database. Consequently, retrieved lncRNAs were compared in literature-based databases including PubMed. As a result, two lists, including experimentally validated lncRNAs and predicted lncRNAs were provided. We found 43 predicted lncRNAs that had not been experimentally validated in GC, so far. Further Bioinformatics analyses were performed to obtain the expression profile of predicted lncRNAs in tumor and normal tissues. Also, the roles and targets of predicted lncRNAs in GC were identified by related databases. Finally, using the GEPIA database was reviewed the significant relationship of predicted lncRNAs with the survival of GC patients. By recognizing the lncRNAs involved in initiation and progression of GC, they may be considered as potential biomarkers in the GC early diagnosis or targeted treatment and lead to novel therapeutic strategies.

Communicated by Ramaswamy H. Sarma     

A prognostic five long–noncoding RNA signature for patients with rectal cancer

This study aimed to identify prognostic long noncoding RNAs (lncRNAs) signature for predicting the prognosis of patients with rectal cancer. LncRNA-sequencing data and clinicopathological data of patients with rectal cancer were retrieved from The Cancer Genome Atlas database. Univariate and multivariate Cox proportional hazards regression analysis, the least absolute shrinkage, and selection operator analysis and the Kaplan-Meier curve method were employed to identify prognostic lncRNAs and construct multi-lncRNA signature. Finally, five lncRNAs (AC079789.1, AC106900.2, AL121987.1, AP004609.1, and LINC02163) were identified to construct a five-lncRNA signature. According to the five-lncRNA signature, patients with rectal cancer were divided into a high-risk group and low-risk group. Patients with rectal cancer had significantly poorer overall survival in the high-risk group than in the low-risk group. We used a time-dependent receiver operating characteristic curve to assess the power of the five-lncRNA signature by calculating the area under the curve (AUC). The AUCs for predicting 3-year survival and 5-year survival were 0.742 and 0.935, respectively, which indicated a good performance of the five-lncRNA signature. The five-lncRNA signature was independently associated with the prognosis of patients with rectal cancer through using univariate and multivariate Cox regression analysis. The biological function of the five lncRNAs was enriched in some cancer-related biological processes and pathways by performing functional enrichment analysis of their correlated protein-coding genes. In conclusion, we developed a five-lncRNA signature as a potential indicator for rectal cancer.     

Profiling and integrated analysis of differentially expressed circRNAs as novel biomarkers for breast cancer

Breast cancer (BC) is a globally common cancer with the highest and increasing morbidity and mortality among females. Novel biomarkers are warranted to be discovered for the early detection, treatment, and prognosis of BC. In this study, we investigated the profiles of differentially expressed (DE) circular RNAs (circRNAs) by competing endogenous RNAs (ceRNA) microarray to construct a genome-wide circRNA profile. Then, we performed Gene Ontology (GO) analysis and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway analysis of the host genes (HGs) of circRNAs. A total of 4,370 DE circRNAs were detected and GO and KEGG analysis showed that they were significantly associated with cell cycle, DNA replication, BC, and familial BC. We validated the differential circRNAs and relevant HGs through quantitative real-time polymerase chain reaction and constructed a putative circRNA–microRNA–messenger RNA regulatory network. Eight circRNAs, including hsa_circ_0069094, hsa_circ_0062558, hsa_circ_0074026, hsa_circ_0079876, hsa_circ_0017536, hsa_circ_0023302, hsa_circ_0017650, and hsa_circ_0017545, were validated significantly DE in BC tissue and associated with TNM staging, lymph node infiltration, and Ki67. Hsa_circ_0069094, hsa_circ_0079876, hsa_circ_0017650, and hsa_circ_0017526 were upregulated in plasma. This study revealed the general expression characteristics of specific DE circRNAs in BC and hsa_circ_0069094, hsa_circ_0079876, hsa_circ_0017650, and hsa_circ_0017526 might be promising candidate targets.